• Newron drops development of sarizotan in Rett syndrome pharmatimes
    May 08, 2020
    Shares in Newron Pharmaceuticals have taken a massive hit from the failure of sarizotan to show a clear benefit in patients with Rett syndrome, a severe neurodevelopmental disorder primarily affecting females.
PharmaSources Customer Service